Will GH core oncology business generate positive FCF in FY2026?
Current Prediction
Why This Question Matters
Core business FCF positivity would demonstrate the oncology franchise is self-sustaining, reducing funding risk.
Prediction Distribution
Individual Predictions(9 runs)
Core business has been approaching profitability with improving gross margins. $30M positive is modest and achievable given the trajectory. Management has consistently executed on operational targets.
Gross margin improvement provides the operational leverage needed. Revenue growth in core products is reliable. The question is whether OpEx discipline holds.
The trajectory supports achievement. Performance-based RSUs hitting 3-year metrics indicates management is executing. Core FCF positivity is the natural evolution of the current trajectory.
Management guided to this specific target. Gross margin trends support it. However, R&D spending could spike on new product development.
Core business profitability has been improving steadily. $30M positive is a small target that should be achievable. Slight risk from allocation methodology between core and Shield.
Strong execution track record plus clear trajectory toward profitability. 60% probability reflects confidence in the operational trajectory.
Core approaching profitability. Guided target is modest. ~58%.
Trajectory supports but execution must hold. ~55%.
Guided target with improving margins. ~58%.
Resolution Criteria
Resolves YES if core oncology business generates positive FCF in FY2026. Resolves NO if negative.
Resolution Source
Guardant Health FY2026 earnings release or management commentary
Source Trigger
Core business FCF guided at ~$30M positive for 2026; would demonstrate oncology franchise is self-sustaining
Full multi-lens equity analysis